Skip to main content
SpringerLink
Log in

Ganstigmine

(CHF 2819)

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. 1This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Warrington S, Johnson N, Cattoni M, Boyce M. Tolerability and pharmacodynamic effects of single doses of ganstigmine, a new cholinesterase inhibitor, in healthymen. British Journal ofClinical Pharmacology. 49: 503P–504P, May 2000.Central Middlesex Hospital, London, England; Chiesi Farmaceutici SpA, Parma, Italy

    Google Scholar 

  2. Johnson N, Cattoni M, Warrington S, Boyce M. Tolerability and pharmacodynamic effects of repeated doses of ganstigmine, a new cholinesterase inhibitor, in healthy men. British Journal of Clinical Pharmacology. 49: 492P–493P, May 2000. Central Middlesex Hospital, London, England; Chiesi Farmaceutici SpA, Parma, Italy

    Google Scholar 

  3. Rocchi M, Mazzucchelli M, Govoni S. The effect of the cholinesterase inhibitors CHF2060 and CHF2819 on the amyloid precursor protein synthesis and metabolism [abstract]. Neurobiology of Aging 2002; 23: S80

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganstigmine. Drugs R&D 3, 355–357 (2002). https://doi.org/10.2165/00126839-200203050-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203050-00012

Keywords

Search

Navigation